Fresenius SE & Co. (OTCMKTS:FSNUY) Shares Shorted: Short Interest Down 85.3% in October

Fresenius SE & Co. (OTCMKTS:FSNUY) saw a large drop in short interest in the month of October. As of October 30th, there was short interest totaling 53,811 shares, a drop of 85.3% from the October 15th total of 367,297 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily volume of 166,740 shares, the days-to-cover ratio is presently 0.3 days.

Fresenius SE & Co. Stock Up 0.0%

Fresenius SE & Co. stock opened at $14.72 on Friday. The firm has a market cap of $33.16 billion, a price-to-earnings ratio of 14.57 and a beta of 0.63. The stock has a fifty day simple moving average of $13.09 and a two-hundred day simple moving average of $12.87. Fresenius SE & Co. has a 12 month low of $10.33 and a 12 month high of $15.94. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.41.

Fresenius SE & Co. (OTCMKTS:FSNUY) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.03. Fresenius SE & Co. had a return on equity of 10.24% and a net margin of 6.58%. The firm had revenue of $6.52 billion for the quarter, compared to the consensus estimate of $6.51 billion. Equities analysts predict that Fresenius SE & Co. will post 1.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

FSNUY has been the topic of several research reports. Deutsche Bank restated a “buy” rating on shares of Fresenius SE & Co. in a research report on Thursday, August 6th. Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. in a report on Tuesday, July 21st. Finally, Citigroup reissued a “buy” rating on shares of Fresenius SE & Co. in a research report on Wednesday, October 28th. Three investment analysts have rated the stock with a Buy rating. According to MarketBeat.com, Fresenius SE & Co. presently has an average rating of “Buy”.

About Fresenius SE & Co.

Fresenius SE & Co. KGaA is a German healthcare group headquartered in Bad Homburg. Its businesses include Fresenius Kabi, which supplies medicines, clinical nutrition, infusion therapies and medical technologies, and Fresenius Helios, which operates hospitals in Germany and Spain. Fresenius Kabi serves healthcare providers around the world, while Helios focuses on hospital and healthcare services in Europe. The group traces its origins to a pharmacy in Frankfurt acquired by pharmacist Eduard Fresenius in 1912.